What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2438.png

Group 2372.png

Dosing and adminstration

 

Dosing options to accommodate your patients1

Frame 427318871.png

Patients previously treated with 2 TKIs: 

 

There is also an option to take SCEMBLIX 40 mg tablets twice a day (AM + PM) 

 

 

Recommended dosage for patients who have the T315I mutation is 200 mg bid AM + PM

Frame 427318848.png

Avoid food consumption for at least 2 hours before and 1 hour after taking SCEMBLIX1

Frame 4273188482.png

Swallow SCEMBLIX whole - do not break, crush, or chew them1

Frame 4273188483.png

SCEMBLIX is available as film-coated tablets: 20 mg (6.2 mm diameter) and 40 mg (8.2 mm diameter)1

Based on pharmacokinetic parameters studied in an exposure-response analysis, the predicted
efficacy and safety profile of SCEMBLIX at the 80 mg qd dose is similar to that at the 40 mg bid dose.1

Missed Dose 

Frame 427318833.png

Once-daily dosage regimen:

  • If a Scemblix dose is missed by more than approximately 12 hours, it should be skipped, and the next dose should be taken as scheduled

Twice-daily dosage regimens: 

  • If a Scemblix dose is missed by more than approximately 6 hours, it should be skipped, and the next dose should be taken as scheduled. 

Dosage reductions

For the management of adverse reactions, reduce the SCEMBLIX dose as described in the table below1

 

Recommended dosage reductions for Scemblix for adverse reactions

Group 2419.png

Dosage modifications for the management of adverse reactions1

Group 2423.png

Qd, once daily; Bid, twice daily; ANC: absolute neutrophil count; PLT: platelets; ULN: upper limit of normal; TKI, Tyrosine kinase inhibitor; PH+ CML-CP, Philadelphia chromosome–positive chronic myeloid leukemia chronic phase

For Scemblix 20mg and 40mg Abbreviated Prescription Information

PDF
View

References

  1. Scemblix Egyptian Drug Authority (EDA) Approved leaflet 05/05/2025

Approved by Egyptian Drug Authority: HF0424OA4707/092025. Invalidation date: 18/09/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at:
www.edaegypt.gov.eg

Scemblix QR Code

HF0424OA4707/092025
18/09/2027

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting